

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D. C. 20231 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/165,546	10/02/1998	KNUTH ALEXANDER	LUD5466.4-JE	8012
24972 75	590 12/14/2001			
FULBRIGHT & JAWORSKI, LLP			EXAMINER	
666 FIFTH AVE			DECLOUX, AMY M	
NEW YORK, N	NY 10103-3198		DECECO!	
			ART UNIT	PAPER NUMBER
			1644	DIC
			DATE MAILED: 12/14/2001	24

Please find below and/or attached an Office communication concerning this application or proceeding.

HLA. AZ

97, 500 (10/15) 1 0.1 0.4 1.4/ 37 (2.10/15) 1 0.1 0.4 1.4/ PTO-90C (Rev. 07-01)

Interview Summary

Application No. **09/165,546**

Applicant(s)

Alexander et al.

Examiner

ner

D Cloux, Amy

Group Art Unit 1644

All participants (applicant, applicant's representative, PTO personnel):				
(1) <u>DeCloux, Amy</u>	(3) <u>Skipper, Thomas</u> (4)			
(2) <u>Hanson, Norman</u> (-				
Date of Interview Dec 11, 2001				
Type: a) ☒ Telephonic b) ☐Video Conference c) ☐ Personal [copy is given to 1) ☐applicant 2) ☐applicant 2)	plicant's representative]			
Exhibit shown or demonstration conducted: d)	If yes, brief description:			
Claim(s) discussed: 74				
Identification of prior art discussed: None				
Substance of Interview including description of the general nature of other comments: Applicant contends that the outstanding 112 first written description disclosure of six peptides of 18 residues each, which bind to HLA-and proliferation of CD4+ cells which are specific for complexes of description of the base claim 74's recitation of a peptide comprising binding motif wherein the first amino acid is Y, F, W or L and the 4th peptides in combination with Futaki et al's teaching of said HLA-Diof the instant claims. Applicant also contends that their invention is instant claims recite peptides of 18-25 amino acids, while the peptides. The examiner agreed to reconsider upon applicant's response (A fuller description, if necessary, and a copy of the amendments vavailable, must be attached. Also, where no copy of the amendments vavailable, must be attached. Also, where no copy of the amendments vavailable, must be attached. Also, where no copy of the amendments vavailable, must be attached. Also, where no copy of the amendments vavailable, must be attached.) i) It is not necessary for applicant to provide a separate reconsider upon applicant as periodic and the peptides of the summary thereof must be attached.)	In rejection should be withdrawn on the grounds that the DR53, wherein three of said peptides stimulate recognition said peptide and HLA-DR53 molecules, is adequate written at 18-25 amino acids, comprising at least one HLA-DR53 is A or S. Applicant contends that the disclosure of said six R53 binding motif, constitutes adequate written description is distinct from the teachings of Futaki et al because the ides taught by Futaki range in length from 11-17 amino is to the outstanding office action. Which the examiner agreed would render the claims allowable, if the substance of the interview (if box is checked). RITTEN REPLY TO THE LAST OFFICE ACTION MUST ection 713.04). If a reply to the last Office action has IIS INTERVIEW DATE TO FILE A STATEMENT OF THE			

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

am De Clare 12/12/01